KalVista Pharmaceuticals, Inc. (KALV)

Market Cap	488.12M
Revenue (ttm)	n/a
Net Income (ttm)	-108.30M
Shares Out	42.19M
EPS (ttm)	-3.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	338,181
Open	11.42
Previous Close	11.50
Day's Range	11.27 - 11.78
52-Week Range	7.21 - 16.88
Beta	0.91
Analysts	Strong Buy
Price Target	26.33 (+127.57%)
Earnings Date	Mar 11, 2024

About KALV

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for ...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Benjamin L. Palleiko
• Employees: 118
• Stock Exchange: NASDAQ
• Ticker Symbol: KALV

Analyst Forecast

According to 3 analysts, the average rating for KALV stock is "Strong Buy." The 12-month stock price forecast is $26.33, which is an increase of 127.57% from the latest price.

Price Target

$26.33

(127.57% upside)

Analyst Consensus: Strong Buy